Navigation Links
Modified-Release Prednisone May Ease Rheumatoid Arthritis

Pill timed to body's rhythms, helps with morning joint stiffness, researchers say

THURSDAY, Jan. 17 (HealthDay News) A modified-release form of the steroid prednisone is better than the standard, immediate-release version at reducing morning joint stiffness in people with rheumatoid arthritis, a new study finds.

German researchers at Charite University Medicine Berlin studied 288 people with active rheumatoid arthritis. Half took standard prednisone (a glucocorticoid) when they woke in the morning and half took modified-release prednisone at bedtime. The modified-release tablets dispense prednisone four hours after ingestion.

After 12 weeks of treatment, patients taking the modified-release version experienced an average of 44 minutes less morning stiffness per day than at the start of the study. That was 29.2 minutes less than those who took the standard version, the team noted.

Their report is published in the Jan. 19 issue of The Lancet.

Both versions have nearly identical total drug exposure and maximum concentration values. They have the same safety profiles.

"Our results have confirmed that the new modified-release formulation is clinically and statistically better than the conventional immediate-release preparation with regard to morning stiffness of the joints. Furthermore, the effects of the new tablet taken at night were achieved in addition to the established clinical control of the disease resulting from previous treatment with conventional immediate-release prednisone," the study authors concluded.

The study was supported by drug maker Merck, which markets the modified-release form of prednisone under the brand name Lodotra.

More information

The Arthritis Foundation has more about rheumatoid arthritis.

-- Robert Preidt

SOURCE: The Lancet, news release, Jan. 17, 2008

Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis
2. Drug Combos Effective Against Rheumatoid Arthritis
3. Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program
4. Combining Medications Often Best Strategy to Battle Rheumatoid Arthritis
5. Geisinger rheumatologists redesign osteoporosis, rheumatoid arthritis care
6. New Test Criteria Spots Rheumatoid Arthritis Sooner
7. Rheumatoid Arthritis Boosts Heart Disease Threat
8. Drugs Can Ease Juvenile Rheumatoid Arthritis
9. Rheumatoid Arthritis Death Rate Unchanged
10. The widening mortality gap between people with rheumatoid arthritis and the general population
11. Researchers identify genes that increase rheumatoid arthritis risk
Post Your Comments:
(Date:11/25/2015)... ... 2015 , ... The McHenry County law firm of Botto Gilbert Lancaster, ... Francisco J. Botto and Alex C. Wimmer. Attorneys Botto and Wimmer represented the claimant ... (2d) 130884WC. , According to court documents, Adcock testified that on May 10, 2010 ...
(Date:11/25/2015)... ... November 25, 2015 , ... SCOTTSDALE, AZ) - Today, ... specializing in both surgical and non-surgical treatments, announced the expansion of his private ... Plastic Surgery. , Highly trained and nationally recognized for his natural approach, ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical ... Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy of its product ... intensive care units (totaling 30 beds) from May 2014 through October 2015 at a ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... provide scholarships for people struggling with eating disorders as a result of the ... second annual event, held at Fox Run Golf Club in Eureka, will help ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... that it has undertaken significant expansion of its current state of the art ... part of PharmaTech’s strategy to increase its manufacturing capacity as well as to ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 25, 2015  Amgen (NASDAQ: AMGN ) today ... with the United States (U.S.) ... biosimilar candidate to Humira ® (adalimumab). Amgen believes ... to the FDA and represents Amgen,s first BLA submission ... Harper , M.D., executive vice president of Research and ...
(Date:11/25/2015)... , Nov. 25, 2015 AAIPharma Services ... investment of at least $15.8  Million to expand ... Wilmington, NC . The expansion will provide ... meet the growing demands of the pharmaceutical and ... site expansion will provide up to 40,000 square ...
(Date:11/25/2015)...  Henry Schein, Inc., the world,s largest provider of ... and animal health practitioners, will unveil at the Greater ... ConnectDental® Pavilion , which brings together for the first ... to help any practice or laboratory enter the digital ... schedule of experts appearing at the Pavilion. --> ...
Breaking Medicine Technology: